IRVING MULTI-PI PLANNING GRANT

Application Instructions

Co-Sponsored by:
Irving Institute for Clinical and Translational Research
The Clinical Trials Office
The Herbert Irving Comprehensive Cancer Center (HICCC)
The Herbert and Florence Irving Institute for Cancer Dynamics (IIICD)

August 2019
Applications are being accepted for this one-year, one-time only, pilot award in the amount of $60,000. These Columbia University Irving Institute/Herbert Irving Comprehensive Cancer Center (HICCC)/Clinical Trials Office/Herbert and Florence Irving Institute for Cancer Dynamics pilot funds are intended to support the submission of multi-component biomedical research grants (e.g. SPORE, U54, P01, P50) and large multi-PI research grants (e.g. NCATS U01, MPI grants that require NIH preapproval). It is expected that the Principal Investigator of those grants will be the pilot award applicant.

Eligibility Criteria for Principal Investigators (PIs):
- Columbia University Irving Medical Center (CUIMC) faculty for non-cancer related projects
- CUIMC and Morningside faculty for cancer related projects

Eligibility Criteria for Projects:
- All multi-component biomedical research grants and large multi-PI research grants by public and private funding agencies will be considered
- Scientific eligibility includes:
  - Translational and/or population research of any disease area;
  - Basic or translational research proposals in cancer; and/or
  - Quantitative approaches to studying cancer, including, but not limited to, early detection, cancer immunology, and spatial single cell technologies, using artificial intelligence (AI), machine learning and related statistical, mathematical or computational methods.

Proposals should describe activities that support the submission of an eligible multi-component/multi-PI grant within 3 months of the end of the pilot 1-year award term.

<table>
<thead>
<tr>
<th>Special Eligibility Considerations</th>
<th>Proposals must include a description of the team and evidence of progress toward submission of an eligible multi-component/multi-PI grant (e.g. established External Advisory Board (EAB), established schedule of team meetings, discussions with a program director/official from the funding agency, etc.).</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>If the relevant eligible multi-component/multi-PI grant has previously been submitted and considered by an external funding agency, evidence of reasonable expectation of funding on resubmission, (e.g. a score and summary statement) and a plan to address the reviewers’ comments, are required.</td>
</tr>
</tbody>
</table>

1
**DIRECTIONS:**

1. **Complete all parts of the Application Form** (contact information for all team members, the project title, abstract, current funding sources, submitted applications, human/animal research approvals, 12-month budget, and budget justification).

   **Budget:** This is a one-time award in the amount of **$60,000**. Your detailed budget should directly support your protocol. Each item must be justified in the budget justification section of the application form. Up to $5,000 can be used to conduct EAB meetings. Expenses may **not** include salary, equipment, or computer costs.

2. **Prepare the body of the application** (i.e., Aims, Team, Grant Planning Survey, and Future Plans). The body of the application should be typed (11 or 12 point font required; Arial typeface preferred) and it should include:
   
   A) **One Specific Aims page for each component of the eligible multi-component/multi PI grant**
      
      - Indicate the multi-component/multi-PI grant that will be supported through this pilot award (funding agency, grant mechanism, and project title, etc.).
      
      - If the proposal is on quantitative approaches to cancer research, clearly indicate what the approaches are.
   
   B) **Team description and structure**
      
      - Include NIH-style biosketches for each MPIs, component leaders, and key/senior personnel: Maximum of 5 pages per investigator (including Other Support)
   
   C) **Pilot Plans:** What is the next step after receiving pilot funding?
      
      - Provide a detailed plan and timeline for submission of the relevant eligible multi-component/multi-PI grant application? This response will be **heavily weighted**.
   
   D) **References:** Reference page(s) do not count towards the four (4) page limit.

3. **Submit the application by selecting the “Submit Your Application” button in the web-based application system,** [https://irvinginstitute.smapply.io](https://irvinginstitute.smapply.io). All applications must be submitted by 5:00p EST on Monday, October 07, 2019.

NOTE: IRB/IACUC approval is not required at the time of application. However, if a candidate is awarded a grant and the project involves the use of data from human and/or animal subjects, an IRB/IACUC approval letter must be forwarded prior to receipt of funding. In order to avoid any delays if funding is awarded, candidates are encouraged to apply and obtain IRB/IACUC approval in advance.

An internal committee organized by the Irving Institute for Clinical and Translational Research, the Herbert Irving Comprehensive Cancer Center (HICCC) and the Herbert and Florence Irving Institute for Cancer Dynamics (IICD) will review and select the awardees. Projects will be evaluated for scientific merit, feasibility, focus, and near-term impact on multi-investigator multi-component grant funding.

---

**FAILURE TO FOLLOW THESE DIRECTIONS WILL RESULT IN THE PROPOSAL BEING RETURNED TO YOU, WITHOUT REVIEW.**

**DO NOT INCLUDE APPENDICES.**

**FUNDING WILL BE AVAILABLE IN EARLY DECEMBER 2019.**
For any questions about the application process, please contact:
Michelle McClave
Associate Director, Program and Communication
Irving Institute for Clinical and Translational Research
mm3098@cumc.columbia.edu

For any questions about the scientific content and eligibility, please contact:

<table>
<thead>
<tr>
<th>Scientific focus</th>
<th>Key Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Translational and/or population research of any disease area</td>
<td>Dr. Akiva Mintz</td>
</tr>
<tr>
<td></td>
<td>Director, Pilot and Collaborative Studies Resource</td>
</tr>
<tr>
<td></td>
<td>Irving Institute for Clinical and Translational Research</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:am4754@cumc.columbia.edu">am4754@cumc.columbia.edu</a></td>
</tr>
<tr>
<td>Basic science research proposals in cancer</td>
<td>Dr. Emer Smyth</td>
</tr>
<tr>
<td></td>
<td>Director, Cancer Research Alliances</td>
</tr>
<tr>
<td></td>
<td>Assistant Dean for Cancer Research</td>
</tr>
<tr>
<td></td>
<td>Assistant Professor, Pathology and Cell Biology</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:es3551@cumc.columbia.edu">es3551@cumc.columbia.edu</a></td>
</tr>
<tr>
<td>Quantitative approaches to studying cancer</td>
<td>Dr. Sophie Thuault-Restituito</td>
</tr>
<tr>
<td></td>
<td>Chief of Staff</td>
</tr>
<tr>
<td></td>
<td>Irving Institute for Cancer Dynamics</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:st3090@columbia.edu">st3090@columbia.edu</a></td>
</tr>
</tbody>
</table>